ArticleBlood cancer journal2020

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.

Tengteng Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.